Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

Cartherics welcomes new PhD Student

By Christine Filippis / March 1, 2021
Monash Grad Rachelle Duffin joins the team 1 March 2021 By Leigh Dayton Fresh from a Research Assistant job at...
Read More

Cartherics Makes February 2021 A Special Month

By Christine Filippis / February 24, 2021
It all happened at Cape Schanck ...... By Leigh Dayton 24 February 2021 2020 was a rough year everywhere for...
Read More

CAR-T Funding is Reaching Staggering New Heights

By Christine Filippis / February 23, 2021
A survey reveals nearly US$100 market capitalisation 23 February 2021 A survey conducted by Washington DC based BioInformant assesses the...
Read More